Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Allarity Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The additional pre-clinical results show that stenoparib demonstrated antiviral activity inhibiting the delta variant in a dose-dependent manner in Vero E6 cells. The delta variant used for the experiments carries an additional deletion in ORF7a, a rapid...
Brand Name : 2X-121
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 11, 2021
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Allarity Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Queensland
Deal Size : Undisclosed
Deal Type : Partnership
International Partnership Progresses UQ COVID-19 Vaccine Project
Details : The UQ team will partner with the Dutch company, Viroclinics Xplore, on the crucial pre-clinical studies.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
April 09, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Queensland
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
